NSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,245.50
- Market cap
- ₹1,25,326 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 27.8×Sector 45.9×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Management Change
Zydus Lifesciences announced the resignation of Dr. Amrut Naik, President of International Markets, effective 7 November 2026. Mr. Christoph Stoller has been appointed to the same senior management role from 2 November 2026.
Zydus Lifesciences Partnership
Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.
Zydus Lifesciences Regulatory Approval
Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.
Zydus Lifesciences Board Meeting Date
Zydus Lifesciences intimated a board meeting on 4 Nov 2026 to approve unaudited Q1/H1 FY27 results. Trading window remains closed until 6 Nov 2026.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited has been assigned an ESG rating of 71 by NSRAL for the financial year 2026. This unsolicited rating reflects the company's sustainability performance.
Zydus Lifesciences Capacity Expansion: ₹190 Cr Investment
Zydus' JV with Sunshine Healthcare signed a BOI agreement to establish a pharma plant in Sri Lanka. Investment exceeds USD 20 million (~₹190 Cr), targeting 2028.
- Value
- ₹190.0 Cr
Other management change announcements
All →NHPC Management Change
NHPC disclosed that Executive Director Shri Vivek Dwivedi's tenure ends on superannuation, effective October 31, 2026. The filing reports no replacement or financial impact.
BEML Management Change
BEML Limited informed exchanges that two senior executives, including the Executive Director (Offg.) Aparup Sinha, ceased office on superannuation effective 31 October 2026. No monetary value is involved.
Jay Jalaram Technologies Management Change
Jay Jalaram Technologies appointed Varjivandas Nathuram Thakkar as Non-Executive Non-Independent Director and Vishnu Harjivanbhai Thaker as Company Secretary. Both appointments are effective 31 October 2026.
Chennai Petroleum Corporation Management Change
Chennai Petroleum's Director (Operations) P. Kannan ceased on superannuation, effective 31 October 2026. S. G. Venkatesh takes additional charge from 1 November 2026.
GAMCO Management Change
GAMCO appointed Jayshri Tulsyan as Non-Executive Independent Director for 24 months, effective October 31, 2026. Ayushi Khaitan resigned as Non-Executive Non-Independent Director, citing personal reasons.
Dhampur Bio Organics Management Change
Dhampur Bio Organics' VP Financial Planning and Analysis, Harmeet Singh, resigned, effective October 31, 2026. It is a senior management departure.